Archives mensuelles : mai 2013

Accueil/2013/mai

Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)

link J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. [...]

Par |2018-06-20T17:30:12+02:00mai 20th, 2013|Pexa-Vec, Publication|Commentaires fermés sur Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Lire la suite

Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)

link J. Lee J, S.Y. Park, J. Burke, H.Y. Lim, [...]

Par |2018-06-20T17:27:41+02:00mai 20th, 2013|Pexa-Vec, Publication|Commentaires fermés sur Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)
Lire la suite
Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166 67405 Illkirch Graffenstaden Cedex - France | Tel. : + 33 (0) 3 88 27 91 00 - Fax. : + 33 (0) 3 88 27 91 11
© 2019 Transgene - All rights reserved
Mentions légales - Crédits